PEPG — PepGen Ltd
NASDAQ · Healthcare · Biotechnology
$3.19
+$0.06 (+2.08%)
PepGen Ltd (PEPG) is a biotechnology company listed on NASDAQ. It is led by James G. McArthur Ph.D., based in 321 Harrison Avenue, Boston, MA, United States, 02118, with about 79 employees. PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Net income was -$18.0M. PEPG currently screens at market cap $39.9M.
Use this PEPG page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PEPG quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PEPG SEC filings page. Lician reads the product cache first so this HTML stays unique to PepGen Ltd even when a live quote feed is slow.
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG Key Statistics
Market Cap
$39.92M
Volume
251,287
Previous Close
$3.07
Day Range
$2.98 – $3.13
EPS
-$2.85
Revenue
$0.00
Net Income
-$89.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
79
PEPG Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$89.98M | -$78.63M | -$69.10M | -$27.28M |
| EPS (Diluted) | -$2.85 | -$3.30 | -$4.42 | -$30.27 |
Total Assets
$150.88M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$49.42M
Operating Cash Flow
-$82.37M
Free Cash Flow
$0.00
PepGen Ltd Company Information
- President, CEO, Treasurer, Secretary & Director
- James G. McArthur Ph.D.
- Headquarters
- 321 Harrison Avenue, Boston, MA, United States, 02118
- Website
- pepgen.com
- Phone
- 781 797 0979
- IPO / Founded
- 2022-05-06
- Sector
- Healthcare
- Industry
- Biotechnology